| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,781 |
16,831 |
130,062 |
1,360,324 |
| Total Sell Value |
$425,515 |
$1,036,298 |
$7,981,599 |
$81,633,859 |
| Total People Sold |
4 |
5 |
8 |
12 |
| Total Sell Transactions |
6 |
12 |
25 |
112 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-06-13 |
4 |
AS |
$61.37 |
$24,548 |
D/D |
(400) |
79,345 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
55,862 |
|
- |
|
| Tannenbaum Renee P |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
26,957 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
79,048 |
|
- |
|
| Leonard Matthew J |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
16,329 |
|
- |
|
| Pera Antonio R |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
35,373 |
|
- |
|
| Thoma Jeanne |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
44,945 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2025-05-15 |
4 |
S |
$60.07 |
$52,922 |
D/D |
(881) |
89,897 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2025-05-14 |
4 |
S |
$60.45 |
$241,800 |
D/D |
(4,000) |
107,317 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-05-13 |
4 |
AS |
$62.20 |
$24,880 |
D/D |
(400) |
79,745 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2025-05-09 |
4 |
AS |
$76.83 |
$53,781 |
I/I |
(700) |
631,920 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-04-14 |
4 |
AS |
$68.96 |
$27,584 |
D/D |
(400) |
80,145 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2025-03-23 |
4 |
D |
$64.26 |
$399,055 |
D/D |
(6,210) |
180,863 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2025-03-23 |
4 |
D |
$64.26 |
$1,121,658 |
D/D |
(17,455) |
468,179 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2025-03-19 |
4 |
AS |
$65.00 |
$121,290 |
D/D |
(1,866) |
64,659 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2025-03-07 |
4 |
AS |
$60.86 |
$60,860 |
D/D |
(1,000) |
66,525 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2025-03-05 |
4 |
S |
$60.00 |
$323,049 |
D/D |
(5,384) |
94,092 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2025-03-05 |
4 |
OE |
$31.49 |
$9,447 |
D/D |
300 |
99,476 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2025-02-28 |
4 |
D |
$61.89 |
$78,910 |
D/D |
(1,275) |
114,191 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2025-02-28 |
4 |
D |
$61.89 |
$756,048 |
D/D |
(12,216) |
502,694 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2025-02-28 |
4 |
D |
$61.89 |
$115,177 |
D/D |
(1,861) |
192,223 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2025-02-28 |
4 |
D |
$61.89 |
$97,167 |
D/D |
(1,570) |
99,176 |
|
- |
|
| Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS |
• – – |
2025-02-28 |
4 |
D |
$61.89 |
$38,805 |
D/D |
(627) |
45,465 |
|
- |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2025-02-28 |
4 |
D |
$61.89 |
$68,017 |
D/D |
(1,099) |
67,525 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2025-02-28 |
4 |
D |
$61.89 |
$68,017 |
D/D |
(1,099) |
80,945 |
|
- |
|
455 Records found
|
|
Page 1 of 19 |
|
|
0.14 (0.21%) 
